Fludarabine
High Grade Malignant Neoplasm
University of WashingtonSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the High Grade Malignant Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Kling Biotherapeutics B.V. | Phase 1/2 | B |
Cladribine University of Washington | Phase 2 | B |
Evomela University of Washington | Phase 2 | B |
FILGRASTIM University of Washington | Phase 2 | B |
CYCLOSPORIN A University of Washington | Phase 2 | B |
View all 18 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →